Biogen Inc. (BIIB) was upgraded to a "buy" by TheStreet's Quant Ratings service on Wednesday. This biotech name has made a chart that could be challenging to many traders and investors. Let's drill down and see if an easier approach to the long side can be found.
More from Stocks
While it may not feel very good, what happened Monday is exactly what this market needed.
Let's instead do the kind of security analysis you have to do if you are going to navigate this moment.
Here's my view on how to react to this public health menace -- both psychologically and as an investor.
EVBG, the critical event management platform, is an intriguing story.